{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:46:40Z","timestamp":1791190000469,"version":"4.1.0"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"933","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The introduction of recombinant human erythropoietin (RHuEPO) has revolutionised the treatment of patients with anaemia of chronic renal disease. Clinical studies have demonstrated that RHuEPO is also useful in various non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection, and perioperative therapies. Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment.<\/jats:p>","DOI":"10.1136\/pmj.79.933.367","type":"journal-article","created":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T19:53:17Z","timestamp":1059767597000},"page":"367-376","source":"Crossref","is-referenced-by-count":74,"title":["Recombinant erythropoietin in clinical practice"],"prefix":"10.1093","volume":"79","author":[{"given":"T","family":"Ng","sequence":"first","affiliation":[{"name":"Phase One Clinical Trials Unit Ltd , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Marx","sequence":"additional","affiliation":[{"name":"Sydney Haematology Oncology Clinic, Hornsby , New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Littlewood","sequence":"additional","affiliation":[{"name":"Department of Haematology, John Radcliff Hospital , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Macdougall","sequence":"additional","affiliation":[{"name":"Department of Renal Medicine, King\u2019s College Hospital (Dulwich) , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,7,1]]},"reference":[{"key":"2023042410211005500_R1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1152\/physrev.1992.72.2.449","article-title":"Erythropoietin: structure, control of production and function","volume":"72","author":"Jelkmann","year":"1992","journal-title":"Physiol Rev"},{"key":"2023042410211005500_R2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(86)92192-6","article-title":"Effects of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis","volume":"ii","author":"Winearls","year":"1986","journal-title":"Lancet"},{"key":"2023042410211005500_R3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N Engl J Med"},{"key":"2023042410211005500_R4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.7326\/0003-4819-111-12-992","article-title":"Recombinant human erythropoietin in anemic patient with end-stage renal disease. Results of a phase III multicenter clinical trial","volume":"111","author":"Eschbach","year":"1989","journal-title":"Ann Intern Med"},{"key":"2023042410211005500_R5","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1073\/pnas.83.18.6920","article-title":"Chromosomal assignment of the human erythropoietin gene and its DNA polymorphism","volume":"83","author":"Law","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042410211005500_R6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1387-2656(08)70055-3","article-title":"The production of recombinant human erythropoietin","volume":"1","author":"Inoue","year":"1995","journal-title":"Biotechnology Annual Review"},{"issue":"3","key":"2023042410211005500_R7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ndt\/16.suppl_3.14","article-title":"An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP)","volume":"16","author":"Macdougall","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2023042410211005500_R8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1523-1755.2001.060002741.x","article-title":"Novel erythropoiesis stimulating protein for the treatment of anaemia in chronic renal insufficiency","volume":"2","author":"Locatelli","year":"2001","journal-title":"Kidney Int"},{"issue":"1","key":"2023042410211005500_R9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1054\/bjoc.2001.1748","article-title":"A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy","volume":"84","author":"Glaspy","year":"2001","journal-title":"Br J Cancer"},{"issue":"1","key":"2023042410211005500_R10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1054\/bjoc.2001.1749","article-title":"Novel erythropoietic stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer","volume":"84","author":"Smith RE Jr, Jaiyesimi","year":"2001","journal-title":"Br J Cancer"},{"key":"2023042410211005500_R11","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood.V88.5.1576.1576","article-title":"Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2","volume":"88","author":"Silva","year":"1996","journal-title":"Blood"},{"key":"2023042410211005500_R12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0272-6386(97)90460-1","article-title":"Effect of recombinant human erythropoietin on lymphocyte phenotyping and phagocyte activity in hemodialysis patients","volume":"29","author":"Huraib","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"2023042410211005500_R13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S1357-2725(99)00071-0","article-title":"The erythropoietin receptor","volume":"31","author":"Tilbrook","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"2023042410211005500_R14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ndt\/13.suppl_2.23","article-title":"Meeting the challenges of a new millennium: optimising the use of recombinant human erythropoietin","volume":"13","author":"Macdougall","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"2023042410211005500_R15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/089686089901900613","article-title":"Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients","volume":"19","author":"Johnson","year":"1999","journal-title":"Perit Dial Int"},{"key":"2023042410211005500_R16","volume-title":"Eprex\u2122 (epoetin alfa) and pure red cell aplasia\u2014contraindication of subcutaneous administration to patients with chronic renal disease","author":"Deputy Chief Medical Officer","year":"2002"},{"issue":"44","key":"2023042410211005500_R17","first-page":"S70","article-title":"Erythropoietin: the promise and the facts","volume":"45","author":"Eschbach","year":"1994","journal-title":"Kidney Int"},{"key":"2023042410211005500_R18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000045834","article-title":"Cardiovascular mortality in haemodialysis patients treated with epoetin beta\u2014a retrospective study","volume":"86","author":"Mocks","year":"2000","journal-title":"Nephron"},{"key":"2023042410211005500_R19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0002-9149(89)90462-1","article-title":"Role of anaemia in the pathogenesis of left ventricular hypertrophy in end stage renal disease","volume":"64","author":"Silverberg","year":"1989","journal-title":"Am J Cardiol"},{"issue":"1","key":"2023042410211005500_R20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/0272-6386(95)90645-2","article-title":"Evidence-based recommendations for the clinical use of recombinant human erythropoietin","volume":"26","author":"Muirhead","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2023042410211005500_R21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/16.2.307","article-title":"Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients","volume":"16","author":"Jungers","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2023042410211005500_R22","first-page":"CD003266","article-title":"Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients (Cochrane review)","volume":"4","author":"Cody","year":"2001","journal-title":"Cochrane Database System Review"},{"key":"2023042410211005500_R23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ndt\/16.suppl_5.45","article-title":"The importance of early treatment of anemia of chronic kidney disease","volume":"16","author":"Eknoyan","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2023042410211005500_R24","first-page":"212","article-title":"The effect of iv iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period","volume":"55","author":"Silverberg","year":"2001","journal-title":"Clin Nephrol"},{"key":"2023042410211005500_R25","first-page":"1","article-title":"Blood transfusion policy","volume-title":"New clinical application nephrology: transplantation","author":"Chapman","year":"1989"},{"key":"2023042410211005500_R26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(88)92616-5","article-title":"Early thrombosis in kidney grafted into patients treated with erythropoietin","volume":"ii","author":"Zaoui","year":"1988","journal-title":"Lancet"},{"key":"2023042410211005500_R27","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(88)90601-0","article-title":"Hemodilution in renal transplantation in patients on eryhtropoietin","volume":"ii","author":"Wahlberg","year":"1988","journal-title":"Lancet"},{"key":"2023042410211005500_R28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69086.x","article-title":"Erythropoietin and renal transplantation","volume":"69","author":"Muirhead","year":"1999","journal-title":"Kidney Int"},{"key":"2023042410211005500_R29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00007890-200101150-00013","article-title":"The use of pretransplant erythropoietin to normalise hemoglobin level: no deleterious effects on renal transplantation outcome","volume":"71","author":"Linde","year":"2001","journal-title":"Transplantation"},{"key":"2023042410211005500_R30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJM199404283301709","article-title":"Erythropoietin and neonatal anaemia","volume":"330","author":"Strauss","year":"1994","journal-title":"N Engl J Med"},{"key":"2023042410211005500_R31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1515\/jpme.1995.23.1-2.119","article-title":"Recombinant erythropoietin for prevention of anaemia in pre-term infants","volume":"23","author":"Obladen","year":"1995","journal-title":"Journal of Perinatal Medicine"},{"key":"2023042410211005500_R32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1345\/aph.19169","article-title":"Factors associated with successful epoetin alfa therapy in premature infants","volume":"34","author":"Reiter","year":"2000","journal-title":"Ann Pharmacother"},{"key":"2023042410211005500_R33","doi-asserted-by":"crossref","first-page":"F96","DOI":"10.1136\/fn.84.2.F96","article-title":"Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary?","volume":"84","author":"Franz","year":"2001","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2023042410211005500_R34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2165\/00019053-199712040-00002","article-title":"Anaemia of prematurity. Epidemiology, management and costs","volume":"12","author":"Meyer","year":"1997","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2023042410211005500_R35","first-page":"1","article-title":"Die Prophylaxe der Fruhgeborenenanamie mit rekombinantem humanen Erythropoietin: eine Kosten-Nutzen-analyse","volume":"203","author":"Schefels","year":"1999","journal-title":"Z Geburtshilfe Neonatol"},{"key":"2023042410211005500_R36","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0022-3468(00)90006-X","article-title":"Erythropoieitn and the incidence of necrotising enterocolitis in infants with very low birth weight","volume":"35","author":"Ledbetter","year":"2000","journal-title":"J Pediatr Surg"},{"key":"2023042410211005500_R37","doi-asserted-by":"crossref","first-page":"F190","DOI":"10.1136\/fn.76.3.F190","article-title":"Randomised controlled double blind study of role of recombinant erythropoietin in the prevention of chronic lung disease","volume":"76","author":"Griffiths","year":"1997","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"2023042410211005500_R38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000014280","article-title":"Use of erythropoietin and its effect on blood lactate and 2,3-diphosphoglycerate in premature neonates","volume":"78","author":"Soubasi","year":"2000","journal-title":"Biol Neonate"},{"key":"2023042410211005500_R39","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V84.4.997.997","article-title":"Recombinant human erythropoietin and the anaemia of cancer","volume":"84","author":"Spivak","year":"1994","journal-title":"Blood"},{"key":"2023042410211005500_R40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1423-0410.2000.7940191.x","article-title":"Red blood cell function and blood storage","volume":"79","author":"Hamasaki","year":"2000","journal-title":"Vox Sang"},{"key":"2023042410211005500_R41","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1537-2995.2001.41121515.x","article-title":"The effect of the transfusion of stored RBCs on intestinal microvascular oxygenation in the rat","volume":"41","author":"van Bommel","year":"2001","journal-title":"Transfusion"},{"key":"2023042410211005500_R42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/cc1070","article-title":"Red blood cell transfusion does not increase oxygen consumption in critically ill septic patients","volume":"5","author":"Fernandes CJ Jr, Akamine","year":"2001","journal-title":"Crit Care"},{"key":"2023042410211005500_R43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/bmj.320.7232.403","article-title":"Prospective investigation of transfusion transmitted infection recipients of over 200,000 units of blood. TTI Study Group","volume":"320","author":"Regan","year":"2000","journal-title":"BMJ"},{"key":"2023042410211005500_R44","first-page":"337","article-title":"Complications of transfusion","volume-title":"Transfusion medicine","author":"McCullough","year":"1998"},{"key":"2023042410211005500_R45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/tm.20000.7395","article-title":"Allogeneic blood transfusion as a risk factor for the subsequent development of non-Hodgkin\u2019s lymphoma","volume":"14","author":"Vamvakas","year":"2000","journal-title":"Transfus Med Rev"},{"key":"2023042410211005500_R46","first-page":"263","article-title":"Autologous transfusion","volume-title":"Practical transfusion medicine","author":"Beatty","year":"2001"},{"key":"2023042410211005500_R47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/rmv.353","article-title":"CMV and blood transfusion","volume":"12","author":"Roback","year":"2002","journal-title":"Reviews in Medical Virology"},{"key":"2023042410211005500_R48","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199006143222401","article-title":"Decreased erythropoietin response in patients with the anemia of cancer","volume":"322","author":"Miller","year":"1990","journal-title":"N Engl J Med"},{"key":"2023042410211005500_R49","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1073\/pnas.081275298","article-title":"Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models","volume":"98","author":"Mittelman","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042410211005500_R50","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jnci\/85.10.801","article-title":"Recombinant human erythropoietin therapy for anemia cancer patients on combination therapy","volume":"85","author":"Case DC Jr, Bukonski","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2023042410211005500_R51","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","article-title":"Recombinant human erythropoietin in cisplatin-associated anemia: a randomised, double-blinded trial with placebo","volume":"12","author":"Casinu","year":"1994","journal-title":"J Clin Oncol"},{"key":"2023042410211005500_R52","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1200\/JCO.1997.15.7.2715","article-title":"Randomised phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia","volume":"15","author":"Del Mastro","year":"1997","journal-title":"J Clin Oncol"},{"key":"2023042410211005500_R53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF02821936","article-title":"Controlled multicenter study of the influence of subcutaneous recombinant erythropoietin on anemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy","volume":"15","author":"ten Bokkel Huinink","year":"1998","journal-title":"Med Oncol"},{"issue":"1","key":"2023042410211005500_R54","first-page":"S19","article-title":"Recombinant human erythropoietin in the treatment of cancer related or chemotherapy-induced anemia in patients with solid tumors","volume":"15","author":"Nowrousian","year":"1998","journal-title":"Med Oncol"},{"key":"2023042410211005500_R55","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.1998.16.10.3412","article-title":"Quality-of-life benefit in chemotherapy patients treated with epoetin-alfa is independent of disease response or tumor type results from a prospective community oncology study, Procrit Study Group","volume":"16","author":"Demetri","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023042410211005500_R56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90213-1","article-title":"The impact of hemoglobin levels on treatment outcomes in patients with cancer","volume":"28","author":"Littlewood","year":"2001","journal-title":"Semin Oncol"},{"issue":"6","key":"2023042410211005500_R57","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0959-8049(01)81022-4","article-title":"Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomised phase III study","volume":"37","author":"Antonadou","year":"2001","journal-title":"Eur J Cancer"},{"key":"2023042410211005500_R58","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.10763","article-title":"Relationship between changes in haemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy","volume":"95","author":"Crawford","year":"2002","journal-title":"Cancer"},{"key":"2023042410211005500_R59","first-page":"526a","article-title":"Clinical and health states assessment in anemic chronic lymphatic leukaemia (CLL) patients treated with epoetin alfa (epo)","volume":"84","author":"Rose","year":"1994","journal-title":"Journal of the American Society of Hematology"},{"key":"2023042410211005500_R60","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1182\/blood.V86.12.4446.bloodjournal86124446","article-title":"Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin\u2019s lymphoma: dose finding and identification of the predictors of response","volume":"86","author":"Cazzola","year":"1995","journal-title":"Blood"},{"key":"2023042410211005500_R61","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood.V87.7.2675.bloodjournal8772675","article-title":"Recombinant human erythropoieitn in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin\u2019s lymphoma\u2014a randomised multicentre study","volume":"87","author":"Osterborg","year":"1996","journal-title":"Blood"},{"key":"2023042410211005500_R62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s005990050032","article-title":"The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy","volume":"28","author":"Dammaco","year":"1998","journal-title":"Int J Clin Lab Res"},{"key":"2023042410211005500_R63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndrome:a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstrom-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"key":"2023042410211005500_R64","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1046\/j.1365-2141.1997.4013211.x","article-title":"Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndrome: proposals of a predictive model","volume":"99","author":"Hellstrom-Lindberg","year":"1997","journal-title":"Br J Haematol"},{"key":"2023042410211005500_R65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0145-2126(00)00073-4","article-title":"Long-term follow-up of 18 patients with myelodysplastic syndrome responding to recombinant erythropoietin treatment","volume":"25","author":"Hast","year":"1999","journal-title":"Leuk Res"},{"key":"2023042410211005500_R66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF01698131","article-title":"Blood transfusion in marrow graft recipients","volume":"65","author":"Pihlstedt","year":"1992","journal-title":"Ann Hematol"},{"key":"2023042410211005500_R67","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/BF02787351","article-title":"Clinical use of rHuEPO in bone marrow transplantation","volume":"16","author":"Klaesson","year":"1999","journal-title":"Med Oncol"},{"key":"2023042410211005500_R68","first-page":"99","article-title":"Autologous blood donation and transfusion","volume-title":"Transfusion medicine","author":"McCullough","year":"1998"},{"key":"2023042410211005500_R69","first-page":"741","article-title":"Recombinant human erythropoietin administration in cardiac surgery","volume":"122","author":"Yazicioglu","year":"2001","journal-title":"J Cardiothorac Surg"},{"key":"2023042410211005500_R70","first-page":"531","article-title":"Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implication for use in gynecologic surgery","volume":"46","author":"Stovall","year":"2001","journal-title":"J Reprod Med"},{"key":"2023042410211005500_R71","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000049723","article-title":"Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation","volume":"33","author":"Wurnig","year":"2001","journal-title":"Eur Surg Res"},{"key":"2023042410211005500_R72","doi-asserted-by":"crossref","first-page":"739","DOI":"10.7326\/0003-4819-117-9-739","article-title":"Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infections and zidovudine therapy. Overview of four clinical trials","volume":"117","author":"Henry","year":"1992","journal-title":"Ann Intern Med"},{"key":"2023042410211005500_R73","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1001\/archinte.1993.00410230087010","article-title":"Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome","volume":"153","author":"Phair","year":"1993","journal-title":"Arch Intern Med"},{"key":"2023042410211005500_R74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00042560-199809010-00004","article-title":"Anemia and survival in HIV infection","volume":"19","author":"Moore","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"2023042410211005500_R75","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0149-2918(00)80081-8","article-title":"Consensus statement: anemia in HIV infection\u2013current trend in treatment options, and practice strategies. Anemia in HIV Working Group","volume":"22","author":"Volberding","year":"2000","journal-title":"Clin Ther"},{"key":"2023042410211005500_R76","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s002960050085","article-title":"Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures","volume":"18","author":"Peeters","year":"1999","journal-title":"Rheumatol Int"},{"key":"2023042410211005500_R77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/03009749950154293","article-title":"Pure red cell aplasia as presentation of systemic lupus erythematosus:antibodies to erythropoietin","volume":"28","author":"Linardaki","year":"1999","journal-title":"Scand J Rheumatol"},{"key":"2023042410211005500_R78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0953-6205(00)00094-7","article-title":"Anemia in inflammatory bowel disease\u2014the role of recombinant erythropoietin","volume":"11","author":"Christodoulou","year":"2000","journal-title":"European Journal of Internal Medicine"},{"key":"2023042410211005500_R79","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.thj.6200022","article-title":"Recombinant erythropoietin therapy as an alternative to blood transfusion in infants with hereditary spherocytosis","volume":"1","author":"Tchernia","year":"2000","journal-title":"Hematology Journal"},{"key":"2023042410211005500_R80","first-page":"431","article-title":"Erythropoieitin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical haemolytic anemia: case reports and literature review","volume":"10","author":"Shapira","year":"2001","journal-title":"J Heart Valve Dis"},{"key":"2023042410211005500_R81","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1749-6632.1998.tb10470.x","article-title":"The role of recombinant human erythropoietin in the treatment of thalassemia","volume":"850","author":"Rachmilewitz","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"2023042410211005500_R82","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1523-1755.2001.00485.x","article-title":"Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure","volume":"59","author":"Nemoto","year":"2001","journal-title":"Kidney Int"},{"key":"2023042410211005500_R83","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1159\/000065304","article-title":"Unexpected renal actions of erythropoietin","volume":"10","author":"Westenfelder","year":"2002","journal-title":"Exp Nephrol"},{"key":"2023042410211005500_R84","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ndt\/16.5.932","article-title":"Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat","volume":"16","author":"Bagnis","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2023042410211005500_R85","article-title":"Effects of two different doses of recombinant human erythropoietin (r-HuEPO) on cisplatin-induced acute renal failure","volume-title":"Proceedings of the American Society of Clinical Oncology","author":"Kurt","year":"2002"},{"key":"2023042410211005500_R86","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1097\/00003246-200008000-00015","article-title":"Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients","volume":"28","author":"van Iperen","year":"2000","journal-title":"Crit Care Med"},{"key":"2023042410211005500_R87","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1097\/00003246-199911000-00004","article-title":"Efficacy of recombinant human erythropoietin in the critically ill patients: a randomised, double-blind, placebo-controlled trial","volume":"27","author":"Corwin","year":"1999","journal-title":"Crit Care Med"},{"issue":"3","key":"2023042410211005500_R88","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/shem.2001.27484","article-title":"Beyond erythropoiesis: novel applications for recombinant human erythropoietin","volume":"38","author":"Cerami","year":"2001","journal-title":"Semin Hematol"},{"key":"2023042410211005500_R89","doi-asserted-by":"crossref","first-page":"9450","DOI":"10.1073\/pnas.142287899","article-title":"Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery experimental spinal cord trauma","volume":"99","author":"Gorio","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042410211005500_R90","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/BF03402029","article-title":"Erythropoietin therapy for acute stroke is both safe and beneficial","volume":"8","author":"Ehrenreich","year":"2002","journal-title":"Mol Med"},{"key":"2023042410211005500_R91","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1388-9842(02)00115-0","article-title":"The importance of anemia and its correction in the management of severe congestive heart failure","volume":"4","author":"Silverberg","year":"2002","journal-title":"European Journal of Heart Failure"},{"key":"2023042410211005500_R92","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/18.1.141","article-title":"The effect of correction of anaemia in diabetes and non-diabetes with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron","volume":"18","author":"Silverberg","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2023042410211005500_R93","article-title":"Blood matters. Quarterly information for hospitals served by the National Blood Service","author":"Robinson","year":"2001"},{"key":"2023042410211005500_R94","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0967-2109(95)00135-2","article-title":"Open-heart surgery in Jehovah\u2019s Witness patients","volume":"4","author":"Chikada","year":"1996","journal-title":"Cardiovasc Surg"},{"key":"2023042410211005500_R95","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00003086-199912000-00026","article-title":"Primary and revision total hip replacement in patients who are Jehovah\u2019s Witnesses","volume":"369","author":"Nelson","year":"1999","journal-title":"Clin Orthop"},{"key":"2023042410211005500_R96","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bmj.311.7013.1115","article-title":"Management of blood loss in Jehovah\u2019s Witnesses","volume":"311","author":"Busuttil","year":"1995","journal-title":"BMJ"},{"key":"2023042410211005500_R97","first-page":"89","article-title":"Blood boosting and sport","volume":"14","author":"Ekblom","year":"2000","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"2023042410211005500_R98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000046676","article-title":"Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients","volume":"22","author":"Bolanos","year":"2002","journal-title":"Am J Nephrol"},{"key":"2023042410211005500_R99","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"key":"2023042410211005500_R100","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJM200205163462015","article-title":"Pure red-cell aplasia and recombinant erythropoietin","volume":"346","author":"Gershon","year":"2002","journal-title":"N Engl J Med"},{"key":"2023042410211005500_R101","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJMoa011931","article-title":"Pure red-cell aplasia and recombinant erythropoietin","volume":"346","author":"Casadevall","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"2023042410211005500_R102","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ndt\/17.suppl_5.42","article-title":"Antibodies against r-HuEPO: native and recombinant","volume":"17","author":"Casadevall","year":"2002","journal-title":"Nephrol Dial Transplant"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/79\/933\/367\/50038984\/postgradmedj-79-367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/79\/933\/367\/50038984\/postgradmedj-79-367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T10:57:50Z","timestamp":1682333870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/79\/933\/367\/7045763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":102,"journal-issue":{"issue":"933","published-online":{"date-parts":[[2003,7,1]]},"published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pmj.79.933.367","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,7]]},"published":{"date-parts":[[2003,7,1]]}}}